Clinical Trial

Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets

Name: Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets — clinical trial record (NCT07694128)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram film coated tablets in fed condition.

Trial Details

NCT Number	NCT07694128
Lead Sponsor	Humanis Saglık Anonim Sirketi
Conditions	Arterial Hypertension (PAH)
Enrollment	30 participants
Start Date	2026-04-08
Primary Completion	2026-06-16 (estimated)
Study Completion	2026-06-22 (estimated)
Updated on ClinicalTrials.gov	2026-07-09